• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …

Cardiomyopathies (CMPs) are myocardial disorders in which the heart muscle is structurally
and functionally abnormal in the absence of abnormal conditions that can explain the …

Abstract Aims The Cardiomyopathy Registry of the EURObservational Research Programme
is a prospective, observational, and multinational registry of consecutive patients with four …

Aims Truncating titin mutations (tTTN) occur in 25% of dilated cardiomyopathy (DCM) cases,
but the phenotype and severity of disease they cause have not yet been systematically …

Introduction We sought to determine prevalence and predictive accuracy of clinical markers
(red flags, RF), known to be associated with specific systemic disease in a consecutive …

Abstract Background and Aims Childhood-onset cardiomyopathies are rare and poorly
characterized. This study examined the baseline characteristics and 1-year follow-up of …

Aims Cardiomyopathies comprise a heterogeneous group of diseases, often of genetic
origin. We assessed the current practice of genetic counselling and testing in the …

Aims Dilated cardiomyopathy (DCM) is a complex disease where genetics interplay with
extrinsic factors. This study aims to compare the phenotype, management, and outcome of …

Aims The interaction between common cardiovascular risk factors (CVRF) and hypertrophic
cardiomyopathy (HCM) is poorly studied. We sought to explore the relation between CVRF …